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Vaccines against antimicrobial resistance (AMR) 
in Enterobacteriaceae
Vaccine projects that are in clinical trial,
prioritizing those in advanced stages of
development.
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Criteria used to include vaccine projects:
Enterobacteriaceae is a family of gram-negative, facultatively anaerobic, non-spore-forming bacillus
that make up a small proportion of intestinal microbiota but are major human pathogens whose
steadily increasing antibiotic resistance poses a significant health threat. This group of nosocomial
pathogens can colonize various sites and cause serious infections among individuals with severe
comorbidities or significant underlying susceptibility factors. Multidrug-resistant microorganisms
(MDRs) have been reported in this order of bacteria.
There is a near static pipeline with only few antibiotics being approved by regulatory agencies in recent
years; however, these are subjected to the appearance of resistance and almost none of them targets
MDRE. In the absence of effective treatment against enterobacterial infections, non-traditional
strategies, such as vaccines may be a feasible option to address this health problem. Prophylactic
vaccines can address AMR though the following mechanisms:
Table 1: Vaccines in clinical development for critical 
Enterobacteriaceae pathogens.*
In this work we review the threat to public health caused by multi-drug resistant
Enterobacteriaceae (MDRE) and assess the role of vaccines as a possible strategy to
prevent infection and decrease the spread of resistance in the selected pathogens.









Incidence of resistant strains in sanitary settlements 
(data extracted from EPINE 2019 report)
Carbapenem resistant 3GC resistant
N/A
Targeted pathogens Key component
E. coli (urinary) Antigens from uropathogenic E. coli (UPEC) combined with a Th1-skewing adjuvant
E. coli (urinary) dmLT with two surface-exposed receptors, Hma or IutA
K. pneumoniae mAb therapy targeting the outer polysaccharide capsule (CPS) of K. pneumoniae
K. pneumoniae
Bioconjugate vaccines, enzymatically produced in glycoengineered E. coli 





Inactivated LPS-null (endotoxin free) whole-cell A. baumannii vaccine 
displaying at the cell surface multiple conserved antigens from P. 
aeruginosa and K. pneumoniae. KapaVax (VXD-005)
K. pneumoniae CPS2 antigen from a carbapenem-resistant K. pneumoniae strain (ST258)
Proteus mirabilis Multi-peptide vaccine of MrpA, UcaA and Pta factors in combination 
with  AddaVax adjuvant
Proteus mirabilis Vaccine based in MrpA and Flagellin as an adjuvant, proposing the fusion 
protein MrpA.FliC as promising vaccine
Targeted pathogens Key component
E. coli (urinary) Multivalent bioconjugate ExPEC4V
E. coli (enteric) Live attenuated, oral vaccine ACE527 with dmLT (mucosal adjuvant)
E. coli (enteric)
and Shigella
ETVAX: inactivated recombinant E. coli strains over-expressing
colonization factors (CFs) and the heat labile toxoid LCTBA
E. coli (enteric)
and C. jejuni
Monoclonal antibody-like recombinant protein, LMN-101 targeting FlaA
(flagellin filament protein)
E. coli (enteric) O-specific polysaccharide of EHECconjugated with recombinant exotoxin A of P. aeruginosa (O157-rEPA)
E. coli (enteric) LT toxin using skin patch
E. coli (enteric) ACE527 ETEC, attenuated live complex
E. coli (urinary) FimH (type 1 fimbrin D-mannose specific adhesin) antagonist,GSK3882347













Violeta Planells i Romeo
Universitat Autònoma de Barcelona
Grau de Biologia 2020-2021
Introduction
Table 2: Summary of promising vaccine candidates in preclinical 
development for critical Enterobacteriaceae.*
Objectives
Methodology
Escherichia coli, Klebsiella 
pneumoniae, Enterobacter spp., Serratia 
spp., Proteus spp., Providencia spp., 
Citrobacter spp. and Morganella spp.
Critical priority 
Enterobacterales
E. coli and K. pneumoniae pose the greatest
concerns because they have a higher burden of
disease and high levels of resistance to third
generation cephalosporins (3GC), β-lactam
antibiotics, carbapenems (CR), fluoroquinolones
and colistin respectively; and at the same time,
both species are part of the normal flora of the
gastrointestinal tract.
Selection of some preclinical projects, including
as much as possible, representation for all the
bacteria studied and reflecting innovative
techniques in vaccinology.
1 2
• Preventing bacterial infections, 
thus, reducing the need for 
antibiotic prescriptions and
minimizing the selective drug 
pressure.
AMR in Enterobacteriaceae
• Reducing occurrence and spread of 
resistant serotypes.
• Decreasing infection rate of 
resistant strains closely related 
(cross-reactivity).
Indirectly Directly
These are facultative pathogens that





Identification of an adequate
population target to develop
prophylactic vaccines is challenging.
Development of previous prophylactic
vaccine candidates has been haltered due
to low incidence in hospital settings and
difficulties in finding a suitable target.
Prophylactic vaccines have to overcome
the economic and logistic barrier of
introducing new vaccines in the health
care system.
• Generate active immunity.
• Licensed prophylactic vaccines can help to 
reduce the incidence of bacterial 
infection in certain population groups at 
risk and indirectly ameliorate antibiotic 
stewardship. 
• Incorporation of new technologies in 
vaccinology and the identification of new 
targets will allow reassessment of 
prophylactic vaccines against 
enterobacteria.
• Many challenges still pending.
• Therapeutic vaccines (with mAb) are
already in the pipeline for E. coli.
• Generate passive immunity.
• Require the pathogen to be identified
before treatment, which can take several
days and thus poses risks to the patient
• Feasible and promising approach.
• In early-stage of development and will
not reach the clinical phase for some
years.










Figure 1: Incidence of resistant critical enterobacteria registered by EPINE 2019 report. 
Advances in vaccinology techniques, together with the identification of new targets, may
allow a change in the vaccine design strategy, towards a more resistant-strain-specific
approach. Prophylactic vaccines that are already in advanced stages of development may
be worth pursuing, however, there are still many challenges directly related to the
opportunistic nature of this pathogens which make this antimicrobial treatment a less
feasible option to address AMR in comparison to other alternative treatments with a
therapeutic approach (e.g., mAb vaccines).




PATHOLOGIES: urinary tract, bloodstream,
intra-abdominal, skin and soft tissue, foodborne
infections and meningitis in neonates.
Vaccine strategies
PATHOLOGIES: pneumonia, bloodstream, 
surgical site, and urinary tract infections.
AMR
fluoroquinolone 





transferfluoroquinolone resistance, ESBLs, 
KPC, OXA-48, TEM










• Opsonophagocytosis of infecting pathogens
• Modulation of T cell immunity
• Neutralization of toxins
